MOTHAFFAR RIMAWI to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Xenograft Model Antitumor Assays.
Connection Strength
0.340
-
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
Score: 0.086
-
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
Score: 0.072
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.030
-
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
Score: 0.028
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.025
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.023
-
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 2014 Apr; 144(2):263-72.
Score: 0.022
-
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
Score: 0.020
-
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121.
Score: 0.019
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.015